ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Post-Mkt 07-15 17:04:54 EDT

14.01

+0.35

+2.53%

盘后14.01

+0.000.00%

16:10 EDT

High14.18	Low13.30	Vol69.55K
Open13.90	D1 Closing13.66	Amplitude6.44%
Mkt Cap125.59M	Tradable Cap64.39M	Total Shares8.97M
T/O957.01K	T/O Rate1.51%	Tradable Shares4.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":14.005,"timestamp":1784145600000,"preClose":13.66,"halted":0,"volume":69552,"hourTrading":{"tag":"盘后","latestPrice":14.005,"preClose":14.005,"latestTime":"16:10 EDT","volume":9,"amount":126.045,"timestamp":1784146204663,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.025256222547584233,"floatShares":4597500,"shares":8967700,"eps":-18.6,"marketStatus":"Post-Mkt","change":0.345,"latestTime":"07-15 17:04:54 EDT","open":13.9,"high":14.18,"low":13.3,"amount":957013,"amplitude":0.064422,"askPrice":14.75,"askSize":30,"bidPrice":14.01,"bidSize":264,"shortable":3,"etf":0,"ttmEps":-18.6,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1784160000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":13.66,"preHourTrading":{"tag":"盘前","latestPrice":13.66,"preClose":13.66,"latestTime":"09:28 EDT","volume":4,"amount":54.64,"timestamp":1784122081044,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.005,"preClose":14.005,"latestTime":"16:10 EDT","volume":9,"amount":126.045,"timestamp":1784146204663,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.811418},"requestUrl":"/m/hq/s/PMN/wiki","defaultTab":"wiki","newsList":[{"id":"2651709721","title":"Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651709721","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651709721?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:15","pubTimestamp":1784027733,"startTime":"0","endTime":"0","summary":"In a report released today, from Guggenheim maintained a Buy rating on ProMIS Neurosciences, with a price target of $35.00. In a report released on...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-promis-neurosciences-pmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-promis-neurosciences-pmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651792051","title":"ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310","url":"https://stock-news.laohu8.com/highlight/detail?id=2651792051","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651792051?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:35","pubTimestamp":1784021745,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (PMN) announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer’s drug candidate, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-reports-amyloid-beta-oligomer-reduction-by-pmn310-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-reports-amyloid-beta-oligomer-reduction-by-pmn310-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651214122","title":"Promis Neurosciences Says Pmn310 Cuts Amyloid-beta Oligomers in Human CSF in Phase 1a Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651214122","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651214122?lang=en_us&edition=fundamental","pubTime":"2026-07-14 14:30","pubTimestamp":1784010633,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences says PMN310 cuts amyloid-beta oligomers in human CSF in Phase 1a dataProMIS Neurosciences reported first human evidence that PMN310 reduced amyloid-beta oligomers in CSF in a Phas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLccRdYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","PMN","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014013.SGD","BK4139","BCDF","BK4585","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651203281","title":"ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651203281","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651203281?lang=en_us&edition=fundamental","pubTime":"2026-07-14 14:30","pubTimestamp":1784010600,"startTime":"0","endTime":"0","summary":"PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326583/0/en/ProMIS-Neurosciences-Reports-First-Human-Evidence-of-Amyloid-Beta-Oligomer-Target-Engagement-by-PMN310-at-AAIC-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649964967","title":"Promis Neurosciences Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649964967","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649964967?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:19","pubTimestamp":1783502340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings(END) Dow Jones NewswiresJuly 08, 2026 05:19 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649937249","title":"ProMIS Neurosciences initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2649937249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649937249?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:10","pubTimestamp":1783455017,"startTime":"0","endTime":"0","summary":"Roth Capital initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $19 price target The firm attributes its bullish view to PMN310...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647455141","title":"Promis Neurosciences Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2647455141","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647455141?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:43","pubTimestamp":1782826980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 09:43 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647253534","title":"Cantor Fitzgerald Initiates ProMIS Neurosciences at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2647253534","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647253534?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:02","pubTimestamp":1782813743,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (PMN) has an average rating of buy and mean price target of $35.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647467584","title":"Indonesia's 2026 Internship Program Offers Up to Rp6mn Monthly Pay","url":"https://stock-news.laohu8.com/highlight/detail?id=2647467584","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647467584?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:30","pubTimestamp":1782793850,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta – Indonesia's National Internship Program (PMN) 2026, launched by the government, offers participants a monthly stipend ranging from Rp3.5 million to Rp6 million, depending on the mi","market":"nz","thumbnail":"https://statik.tempo.co/data/2026/06/29/id_1479922/1479922_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/06/29/id_1479922/1479922_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2111073/indonesias-2026-internship-program-offers-up-to-rp6mn-monthly-pay","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2111073/indonesias-2026-internship-program-offers-up-to-rp6mn-monthly-pay","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645209892","title":"Promis Neurosciences Price Target Maintained with a $18.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645209892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645209892?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:02","pubTimestamp":1782298920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings(END) Dow Jones NewswiresJune 24, 2026 07:02 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641433885","title":"ProMIS Neurosciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641433885","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641433885?lang=en_us&edition=fundamental","pubTime":"2026-06-08 23:47","pubTimestamp":1780933620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 11:47 ET (15:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638913266","title":"ProMIS Neurosciences to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2638913266","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638913266?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:13","pubTimestamp":1779977631,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, 11:40 a.m.–12:10 p.m. ET.Virtual Alzheimer’s R&D Day hosted by Wolfe Research set for June 4, 2026, 8:30 a.m.–9:00 a.m. ET; invitation-only.Presentation planned for June 15, 2026 at the H.C. Wainwright Neuro Perspectives Expert Summit in New York.One-on-one meetings slated at the BIO International Convention in San Diego on June 22–25, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL8l9Djd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","BK4112","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP","SG9999014021.USD","BK4585","NDAQ","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638662691","title":"ProMIS Neurosciences to Participate in Upcoming Conferences in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2638662691","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638662691?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:13","pubTimestamp":1779977580,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  28, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303024/0/en/ProMIS-Neurosciences-to-Participate-in-Upcoming-Conferences-in-June.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637887318","title":"ProMIS Neurosciences shareholders approved 900,000-share increase to 2025 incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2637887318","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637887318?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:33","pubTimestamp":1779309182,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences held its annual shareholder meeting on May 20, 2026.Shareholders backed an amendment to the 2025 Stock Option and Incentive Plan, increasing the share pool available for issuance under the plan by 900,000 shares; the amendment became effective upon that approval.The appointment of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026 was ratified.Director nominees were elected to serve until the 2027 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Ex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL83cGxq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636584668","title":"ProMIS Neurosciences initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636584668","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636584668?lang=en_us&edition=fundamental","pubTime":"2026-05-20 18:26","pubTimestamp":1779272762,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $40 price target Published first on TheFly – the ultimate source f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","PMN","BRKL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071800","title":"MindWalk reports 10 partner-owned antibody programs in active Phase 1-3 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636071800?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:55","pubTimestamp":1779112530,"startTime":"0","endTime":"0","summary":"MindWalk Holdings released a report in May 2026 attributing more than 20 drug candidates that reached clinical trials to antibody discovery work conducted at its facilities.Ten partner-owned programs were described as active in Phase 1 to Phase 3 trials across oncology, immunology, neurology, infectious disease.Examples cited included Annexon’s ANX005 in Phase 3 for Guillain-Barré syndrome, argenx’s ARGX-119 in Phase 2/3 for congenital myasthenic syndrome, ProMIS Neurosciences’ PMN310 in Phase 1b for Alzheimer’s disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2hykl3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","PMN","HYFT","ANNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635532020","title":"Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635532020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635532020?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:50","pubTimestamp":1778881809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN) and Evolent Health (EVH) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-promis-neurosciences-pmn-evolent-health-evh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-promis-neurosciences-pmn-evolent-health-evh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","LU0128526141.USD","EVH","XBI","XLV","LU0029874061.USD","BK4588","PMN","LU0053671581.USD","HCSG","BK4167","LABU","BK4137","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212795","title":"ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634212795?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:34","pubTimestamp":1778592888,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings SummaryProMIS Neurosciences Inc PMN.OQ reported a quarterly adjusted loss of $1.26 per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P1Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634185532","title":"ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634185532","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634185532?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:57","pubTimestamp":1778583441,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of $(5.25) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52479480/promis-neurosciences-q1-eps-1-26-beats-1-48-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290396","title":"ProMIS Neurosciences Q1 FY26 net loss widens to $8.24 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634290396?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:30","pubTimestamp":1778581852,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences posted a net loss of $8.2 million, widening from $7.3 million a year earlier.Operating loss widened to $8.6 million as operating expenses climbed to $8.6 million, led by R&D spending of $7 million.Cash and cash equivalents rose to $63.8 million following a February private placement that brought in $75.5 million in gross up-front proceeds.PRECISE-AD Phase 1b trial of Alzheimer’s candidate PMN310 is fully enrolled with 144 participants, with a blinded 6-month interim safety and biomarker analysis expected in early Q3 2026.Cash runway is expected to fund operations through 2027, including completion of the PRECISE-AD trial, with unblinded 12-month top-line data anticipated in early 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL50gcF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","PMN","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014013.SGD","BK4139","BK4585","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.3198},{"period":"3month","weight":0.1106},{"period":"6month","weight":0.6753},{"period":"1year","weight":0.0508},{"period":"ytd","weight":1.0015}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.492325},{"month":2,"riseRate":0.5,"avgChangeRate":0.1186},{"month":3,"riseRate":0,"avgChangeRate":-0.161081},{"month":4,"riseRate":0.5,"avgChangeRate":0.06597},{"month":5,"riseRate":0,"avgChangeRate":-0.137867},{"month":6,"riseRate":0.25,"avgChangeRate":-0.061162},{"month":7,"riseRate":0.5,"avgChangeRate":0.082048},{"month":8,"riseRate":0,"avgChangeRate":-0.185569},{"month":9,"riseRate":0.5,"avgChangeRate":-0.048217},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042317},{"month":11,"riseRate":0,"avgChangeRate":-0.242658},{"month":12,"riseRate":0.5,"avgChangeRate":-0.058437}],"exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction